About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

PAL's picks - Clinical Trials of Interest 

By Type of Lymphoma:
AIDS/HIV-related | ALCL | Burkitt's | CLL/SLL |  CNS Lymphoma
DLBCL |  Follicular | Hodgkin  | Mantle Cell | Marginal Zone (MALT) 
T-cell LymphomasMixed types of lymphoma
WM |
GVHD ....                What's New?
Trial Talk  to find an expert in your region to help you decide if a study is a good decision based on your unique circumstance
Find Trials for Lymphoma or CLL:  Alphabetical  | New since Jan 2016  | Phase I since 2014  | Phase III since 2014

 
Trials of interest

Last update: 01/09/2017  

WHAT'S NEW

bullet
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma http://bit.ly/2ia1qVE
bullet
DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Alliance Trials http://bit.ly/2i72jn2
 
bullet
Relapsed Indolent Lymphoma (FL, MZL ..)
Testing Lenalidomide (immune-modulator)
and GA101 (cd20 mab)  Open

New
bullet
Testing safety of TGR-1202 (PI3K-delta Inhibitor)
and Ibrutinib (btk-inhibitor)
for Relapsed and Refractory Diffuse Large B-Cell Lymphoma http://bit.ly/2bRW6po
bullet
Denintuzumab Mafodotin
(SGN-CD19A antibody-drug conjugate)
With RCHOP/RCHP VS RCHOP in DLBC or FL Lymphoma http://bit.ly/2amcOPr

Report on Phase 1 safety:  http://bit.ly/2aXcLdS
 
bullet
Targeting a validated immune-pathway target in novel way:

Testing CA-170 (small molecule, Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) for advanced cancer and Lymphomas http://1.usa.gov/28W6he3 
bullet
Testing Gene Therapy for HIV Virus-Related Lymphoma Receiving Stem Cell Transplant  http://1.usa.gov/1U4l4Pq 
bullet
Elderly (75+yrs.) With previously untreated DLBC Lymphoma
Testing Brentuximab Vedotin (antibody-drug conjugate), with Rituxan, and with Dose Attenuated CHP (CHOP minus vincristine)  http://1.usa.gov/1Stlnoc
bullet
Relapsed / refractory B-cell Lymphoma
Testing Oral Selinexor for Receiving R-DHAOx or R-GDP http://1.usa.gov/1YGTQkX
bullet
Follicular Lymphoma, previously untreated
without a current need to treat
Testing Rituximab (cd20 antibody) With or Without Zevalin (radio-labeled cd20 antibody) Open  
Clicks as of 4/6/16:  91  Today: >
bullet
Follicular lymphoma, previously untreated
Testing Intratumoral G100 (TLR4 agonist) +/- Pembrolizumab (anti-pd1 antibody - immune checkpoint inhibitor)  Open
17  Today: >
bullet
Find Trials for Lymphoma or CLL:  
Alphabetical  | New since Jan 2016 
Phase I since 2014  | Phase III since 2014
bullet
Adding the following queries to each:
By treatment status
- to limit list of trials to your setting
Phase I trials - to see what is newest - just emerging
Open Phase III controlled trials - to see potentially practice changing studies that you might also consider
bullet
CLL -- Richter's Transformation
Testing
PNT2258 (BCL-2-targeted liposomal packaging of 24-base DNA oligonucleotide )  Open
bullet
AIDS/HIV-related lymphoma studies
bullet
ALCL studies
bullet
Burkitt's studies
 



  
 

This resource is intended as an aid in the discussion of trials.


Requiring NO registration
or disclosure of personal information
.

It's about advancing research, yes,
but also it's about increasing the number and types of choices
 for patients when treatment is needed.

 


AIDS / HIV-related lymphomas 
 

bullet
Locate trials for AIDS / HIV-related lymphoma
Open Controlled Studies Click count: >
By treatment status:
Untreated  > | Relapsed  >
bullet
Testing EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection Open
bullet
HIV-Related Aggressive B-Cell Lymphomas
Testing Vorinostat and Combination Chemotherapy With Rituximab in  Open
bullet
AIDS-related Primary Brain Lymphoma
Testing
Chemotherapy and HAART  Open

 

 

 
Anaplastic Large Cell (ALS) Lymphoma

bullet
Locate trials for for lymphoma
Open Phase III Controlled trials  Click count: >
Open Phase I trials  >
By treatment status:
Untreated  > | Relapsed >
bullet

Comparing Brentuximab Vedotin and CHP With CHOP in CD30-positive Mature T-cell Lymphomas Open

 

 


Burkitt's Lymphoma 

bullet
Locate trials for Burkitt's lymphoma
Open Controlled Studies Click count: >
By treatment status:
Untreated  > | Relapsed  >

 

 


CLL/SLL 

 See also
lymphoma, mixed types

bullet
Locate trials for CLL/SLL
Open Phase III Controlled trials Click count: >
Phase I trials >
By treatment status:
Untreated  > | Relapsed  >
bullet
CLL -- Richter's Transformation
Testing
PNT2258 (BCL-2-targeted liposomal packaging of 24-base DNA oligonucleotide )  Open
bullet
CLL and SLL, untreated with need to treat
Comparing Ibrutinib + Rituximab to FCR (chemoimmunotherapy)  Open
bullet
Buparlisib
bullet
CLL, relapsed or refractory
Testing Lenalidomide, Rituximab and Ibrutinib  Open
bullet
CLL or Aggressive lymphoma including transformed, relapsed or refractory
Testing Selinexor  /KPT-330 and Ibrutinib  
   
bullet
CLL
Testing Idelalisib With BI 836826 (anti-cd37) in CLL
bullet
Buparlisib

Return to Top


 

CLL/SLL
From our picks that are no longer recruiting.

bullet
CLL/SLL Relapsed or Refractory with 17p Deletion
Testing: 
ABT-199 an inhibitor of BCL-2 
Clicks as of 6/13/14: 123 Today: >
bullet
CLL / SLL, relapsed requiring treatment
Expanded Access Idelalisib in Combination With Rituximab
Clicks as of 8/13/14: 56 T
oday: >
bullet
CLL / SLL relapsed < 36 months after last treatment with current need to treat
Comparing
: Idelalisib With Bendamustine VS Rituxan VS Bendamustine and Rituxan Clicks as of 4/27/14: 88 Today: >  
bullet
CLL / SLL relapsed OR previously untreated, OR no prior transplant
 Testing
: ABT-199 WITH Rituxan

Clicks as of 6/13/14170 Today: >
bullet

CLL/SLL Relapsed or Refractory
Comparing
: Bendamustine-Rituxan (B-R) to B-R with Ibrutinib 
Clicks as of 4/27/14
127 Today: >

bullet
CLL / SLL with current need to treat, over 65 years of age OR having 17p or p53 risk factors
Testing
: Ibrutinib
 
Clicks as of 10/18/13:
104
 Today: >  
bullet
CLL / SLL  previously untreated, - elderly (over 65 years)
Comparing: Lenalidomide VS Chlorambucil As First Line Therapy  (The ORIGIN Trial  Clicks as of 10/18/13: 72  Today: > 
bullet
CLL / SLL previously untreated OR relapsed, need to treat, no transformation Comparing Ibrutinib WITH FC-Rituxan VS Bendamustine-Rituxan   Clicks as of 10/18/13: 156 Today:  > 
bullet
CLL / SLL relapsed <24 months since last treatment with
current need to treat, AND not eligible for chemo
Comparing: Idelalisib (GS-1101 / CAL101) with Rituxan VS Rituxan with Placebo 
Clicks as of 10/18/13: 72 Today: > 
bullet
CLL / SLL relapsed or refractory
Comparing IPI-145 Versus Ofatumumab  (DUO) 

Clicks as of
1/28/16: 64
  Today: >
bullet
CLL / SLL Early-Stage Asymptomatic
Testing Lenalidomide + Vaccine
Clicks as of
1/28/16: 62 T
oday: >

 

 
 CNS Lymphoma - Central Nervous System  Lymphoma

bullet
Locate trials for CNS Lymphoma
Open Phase III Controlled Studies  (fixed) >
By treatment status: Untreated  | Relapsed
bullet
CNS Lymphoma, primary
Testing: 
Ibrutinib and Immuno-Chemotherapy Using
Dose-Adjusted Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (DA-TEDDI-R) http://1.usa.gov/1hbcH8j 

Patients Summary | Trial Summary (PDF) 
14 Today: >
bullet
CNS Lymphoma - primary, previously untreated
Testing: Chemo WITH or WITHOUT Autologous Stem Cell Transplant
Study drug reports  : 33 Today: >
bullet
CNS / intraocular Lymphoma relapsed or refractory 
Testing: Lenalidomide WITH Rituxan
Study drug reports : 61 Today: > 

Return to Top
 

 
 

CNS Lymphoma
From our picks that are no longer recruiting

(to be added)


 DLBCL (Diffuse Large B-Cell Lymphoma)

 See also Lymphoma - mixed types, aggressive

bullet
Locate trials for DLBCL
Open Phase III Controlled studies  (fixed) >
By treatment status:
Untreated | Relapsed
DLBCL with c-myc genetic change
bullet
DLBCL - previously untreated
Testing Denintuzumab Mafodotin
(SGN-CD19A antibody-drug conjugate)
With RCHOP/RCHP VS RCHOP in DLBC or FL Lymphoma http://bit.ly/2amcOPr

Report on Phase 1 safety:  http://bit.ly/2aXcLdS
 
bullet
DLBCL, PMBCL type, relapsed
Testing Pembrolizumab (pd-1 immune checkpoint inhibitor)
: 16 Today: > 
bullet
DLBCL, previously untreated
Testing Pembrolizumab (pd1 antibody) with R-CHOP
: 16 Today: > 
bullet
DLBCL, newly diagnosed
Testing Rituximab and Combination Chemotherapy With or Without Lenalidomide for Newly Diagnosed Stage II-IV DLBC Lymphoma Open
: 27 Today: > 
bullet
DLBCL, relapsed - including transformed from FL
Testing MDV9300 (anti-pd-1) in R/R Diffuse Large B-cell Lymphoma (DLBCL) including transformed
: 26 Today: > 
bullet
DLBCL, ABC subtype, relapsed
Testing ACP-196 (Btk Inhibitor) for relapsed Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma Open 
: 88 Today: > 
bullet
DLBCL, relapsed
Testing
PNT2258 (first-in-class DNAi ) for Pretreated Diffuse Large B-Cell Lymphoma (Wolverine) Open
: 34 Today: > 

ASH 2013: Paper: The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma Report
Reports http://bit.ly/1B9gKGD | http://1.usa.gov/Z53YLF
bullet
DLBCL newly diagnosed, ABC subtype
Comparing Ibrutinib + CHOP-R VS CHOP-R 
27  Today: >
bullet
DLBCL relapsed or refractory
Testing Ibrutinib + Lenalidomide, With and Without Rituxan 
80  Today: >

Return to Top
 


 
 
DLBCL
From our picks that are no longer recruiting
bullet
DLBCL relapsed, not eligible for transplant or failed last transplant
Testing
Nivolumab (immune checkpoint inhibition)
  42  Today: >
bullet
DLBCL previously untreated
Comparing
Zevalin to Observation AFTER Standard R-CHOP 
 67  Today: > 
(Terminated)
bullet
Lymphoma, mixed aggressive - DLBCL including transformed
relapsed or refractory AND not eligible for transplant
Testing
5-azacitidine (epigenetic agent) WITH Vorinostat (HDAC inhibitor)
Study drug reports Clicks as of 4/27/14: 69  Today: 
bullet
DLBCL or transformed follicular with CD79 Mutation
Testing
AEB071 a Protein Kinase C Inhibitor
 Clicks as of 4/27/14: 67  Today: > 
(Terminated)


DLBCL previously untreated
Testing
5-azacitidine (epigenetic) WITH R-CHOP (standard therapy)
Clicks as of 4/27/14: 18  Today: >
(needs verification)
bullet
DLBCL previously untreated
Testing
5-azacitidine (epigenetic) WITH R-CHOP (standard therapy)
  Clicks as of 4/27/14: 43  Today: >
bullet
DLBCL including subtypes, previously untreated
Comparing
CHOP-R to EPOCH-R 
  Clicks as of 4/27/14152 Today: 
bullet

DLBCL relapsed or refractory
Testing
Ibrutinib (Bruton's Tyrosine Kinase Inhibitor
)

Study drug reportsClicks as of 4/27/14 43  Today:  > 

 

 
 Follicular lymphoma

  See also lymphoma, mixed types
 

bullet
Locate trials for Follicular Lymphoma
Open Phase III Controlled studies Click count: >
Phase I studies >
By treatment status:
Untreated | Relapsed
bullet
Follicular Lymphoma, previously untreated
without a current need to treat
Testing Rituximab (cd20 antibody) With or Without Zevalin (radio-labeled cd20 antibody) Open  
Clicks as of 4/6/16:  91  Today: >
bullet
Follicular, previously untreated
Testing Intratumoral G100 (TLR4 agonist) +/- Pembrolizumab (anti-pd1 - immune checkpoint inhibitor)  Open
17  Today: >
bullet
Follicular Lymphoma, relapsed, refractory to Rituxan
Testing IPI-145 With Rituximab vs Rituximab in Previously Treated Follicular Lymphoma - ClinicalTrials.gov Open  
63  Today: >  Report 
bullet
Follicular, relapsed/refractory
Testing Nivolumab (immune checkpoint blockade) in  Lymphoma Open
63  Today: >

Key eligibility:  > or = 2 prior treatment lines; each of the 2 prior treatment lines must include at least Rituximab and/or an Alkylating agent
bullet
Follicular lymphoma, untreated, without symptoms
Testing Rituximab With or Without Zevalin in Treating Patients With Untreated, Asymptomatic Follicular Lymphoma Open  
61  Today: >
bullet
Follicular lymphoma, advanced stage, previously untreated
Testing
Response-adapted Strategy (molecular response by MRD) following standard RCHOP
: 26 Today: >
bullet
Follicular lymphoma, relapsed or refractory
Comparing ABT-199 + Bendamustine + Rituximab (BR) TO BR or ABT-199 + R
Study drug reports : 61 Today: >
bullet
Follicular lymphoma previously untreated, measurable disease but not bulky
Testing
Veltuzumab (cd20 antibody) AND Fractionated 90Y- Epratuzumab Radioimmunotherapy

Study drug reports : 71  Today: > 
 

Return to Top

 

 

 
bullet
Follicular lymphoma stage I or II, grade I or II
- previously untreated

Testing
Radiation Therapy WITH Rituxan
Clicks as of 7/30/15: 72 Today: >

(Status not known)
Follicular Lymphoma
From our picks that are no longer recruiting
 
bullet
Follicular lymphoma, refractory
Testing Ibrutinib as single agent

Study drug reports  Clicks as of 7/30/15: 101 Today: >
 
bullet
Follicular Lymphoma, previously untreated
Testing
Ibrutinib, Lenalidomide, and Rituxan

Clicks as of
7/30/15: 115  Today: >
bullet
Follicular lymphoma grade 1-3a, stage II-IV - previously untreated with current need to treat
Testing Lenalidomide with RITUXAN followed by Rituxan maintenance  OR
Rituxan-based chemotherapy followed by Rituxan Maintenance

Clicks as of 7/30/15: 91 Today: >
bullet
Follicular lymphoma relapsed - responded to prior Rituxan-based treatment
Testing Idelalisib (GS-1101 / CAL101) WITH Lenalidomide AND WITH Rituxan

Clicks as of
7/30/15: 139  Today: >
bullet
Follicular lymphoma relapsed, responsive to last Rituxan
Testing: Lenalidomide, OR Rituxan, OR Rituxan WITH Lenalidomide

Clicks as of 10/18/13: 132  Today: >

 

 
Hodgkin Lymphoma

 See also Lymphoma - mixed, aggressive, and indolent

bullet
Locate trials for Hodgkin Lymphoma
Open Phase III Controlled studies 
By treatment status:
Untreated  | Relapsed
bullet
Hodgkin Lymphoma, relapsed or refractory
Testing Mocetinostat (HDAC inhibitor) with Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Open 
: 22  Today: > 

mocetinostat NCI Drug dictionary - cancer.gov 
bullet
Hodgkin Lymphoma, relapsed or refractory
Testing
Ipilimumab and Brentuximab Vedotin

Study drug reports   74  Today: 
bullet
Hodgkin Lymphoma stage II-IV, previously untreated, age 60 years or older
Testing
Brentuximab Vedotin AND Combination Chemotherapy (ADV)
Study drug reports Clicks as of 10/19/1335 Today: >
bullet
Hodgkin Lymphoma primary refractory OR relapsed
Testing
Radiolabeled Monoclonal Antibody Therapy AND Combination Chemotherapy BEFORE Stem Cell Transplant

51   Today: > 

Return to Top

 

 

 

Hodgkin Lymphoma
From our picks that are no longer recruiting
 
bullet
Hodgkin Lymphoma relapsed after autologous transplant OR at least 2 prior multi-agent chemotherapy regimens in patient not eligible for transplant
Testing 
PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin
 
  57  Today:  >
bullet
Hodgkin Lymphoma relapsed or refractory, no prior salvage therapy
Testing
Brentuximab Vedotin WITH Bendamustine
 
 Clicks as of 10/19/13 47  Today:  >
bullet

Hodgkin Lymphoma, relapsed or refractory
Testing
PI3K Delta Inhibitor TGR-1202, Given With Brentuximab Vedotin
Study drug reports  57  Today:   

bullet

Hodgkin Lymphoma, untreated stage I/II, non-bulky
Testing
ABVD chemotherapy - Intensity and Type of Chemo Based on Result of PET Scan

  28  Today:  > 

 


 
 Lymphoma - mixed types in same trial

 See also: DLBCL | Hodgkins | CLL / SLL | Follicular | Mantle Cell | T-cell

bullet
Locate trials for mixed types of lymphoma or CLL
All Studies 
By treatment status:
Phase III - open Controlled studies
Phase I: All types | CLL | NHL | HL
Mixed aggressive section
bullet
Lymphoma, mixed:
DLBCL & transformed, relapsed or refractory

  Testing denintuzumab mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for DLBC Lymphoma  Open 
7   Today: > 
bullet
n B-cell Lymphoma
Biopsy-proven refractory after frontline chemo-immunotherapy Open  
17   Today: > 

Relapsed or refractory B-cell NHL, including
Diffuse large B-cell lymphoma (DLBCL) and
DLBCL not otherwise specified (NOS)
Transformed DLBCL from indolent histology and

Follicular lymphoma Grade 3B.

 
bullet
Lymphoma, mixed b-cell types,
aggressive lymphoma, cd20-positive, relapsed
  Testing
Belinostat (HDAC inhibitor) WITH Zevalin
 
Key eligibility: CD20 positive DLBCL, MCL, high grade-B-cell or anaplastic large B cell NHL;
AND bone marrow =< 20% involvement; first relapse eligible if not a candidate for transplant.

Study drug reports  Clicks as of 4/27/14: 63 Today: >
bullet
Lymphoma, mixed
aggressive types relapsed or refractory
  Testing KPT-330 + RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma, including transformed FL Open
49   Today: > 

Technical Background Report
 
bullet
Lymphoma, mixed b-cell types:
relapsed and refractory to chemotherapy
  Testing Adoptive T-cell therapy:  Genetically Engineered Lymphocyte Therapy

Study drug reports Clicks as of 4/27/1433 Today: > (China)
bullet
Lymphoma, mixed b-cell types:
NHL OR CLL cd-19 positive
, high-risk, refractory to chemotherapy including FL, MCL, and DLBCL
   Testing  Adoptive T Cells therapy engineered to target CD19

Clicks as of
4/27/1449  Today: >  

Key eligibility: CD19+ B cell lymphomas
with no available curative treatment options (such as autologous or allogeneic SCT)
Mixed Aggressive or Indolent section
bullet
Lymphoma, mixed b-cell types: - transformed from indolent
  Testing
Ibrutinib
Study drug reports 
Clicks as of 8/13/14: 35 Today: 
bullet
Lymphoma, mixed b-cell types - relapsed or refractory
  Testing
Ibrutinib with Lenalidomide

Study drug reports  Clicks as of 4/27/14: 107 Today: 
bullet
Lymphoma, mixed b-cell types: low or high grade - including DLBCL, relapsed and refractory
  Testing
DCDT2980S OR DCDS4501A (antibody - drug conjugates) WITH Rituxan

Study drug reports  Clicks as of 4/27/14: 59  Today: >   
bullet
38   Today: >   
bullet
Lymphoma, mixed b-cell types, indolent
Testing Duvelisib (IPI-145) With Rituximab (R) & Bendamustine (B) vs BR +Placebo  - Open
27  
bullet
Relapsed Indolent Lymphoma (FL, MZL ..)

Testing Lenalidomide (immune-modulator)
and GA101 (cd20 mab)  Open
New
bullet
Lymphoma, mixed b-cell types, relapsed
  Testing Ibrutinib Given With Nivolumab in Participants With Hematologic Malignancies - Open
51 Today: >   
bullet
Lymphoma -  mixed b-cell types,  relapsed or refractory
Testing Daratumumab  (anti-cd38) in Relapsed/Refractory b-cell lymphoma - Open
44   Today: > 
bullet
Lymphoma -mixed b-cell types, relapsed or refractory
  Testing Lenalidomide + Rituximab THEN: Lenalidomide OR Rituxan Maintenance for Relapsed/Refractory FL, MCL, MZL Lymphoma Open
49   Today: > 

Discussion:  http://bit.ly/1DGFtTU
bullet
Lymphoma, mixed types:
follicular or DLBCL, relapsed or refractory
  Testing Polatuzumab Vedotin With cd20 antibody With Bendamustine in Relapsed or Refractory Follicular DLBC Lymphoma Open
59   Today: > 

* About Polatuzumab Vedotin http://bit.ly/ZXRo1t
bullet
Lymphoma, mixed types:
Indolent b-cell lymphoma,
relapsed, responded to last Rituxan therapy, no transformed

  Comparing Idelalisib + Bendamustine-Rituxan VS  Bendamustine-Rituxan
Participants have a 2:1 chance of being assigned to Idelalisib-based treatment group
Study drug reports : 113 Today: >
bullet
Lymphoma, mixed types:
NHL, CLL, or Hodgkins
  Testing LAG-3 antibody, safety study anti-LAG-3 monoclonal antibody BMS-986016
Study drug reports : 39  Today: > 
bullet
Lymphoma, mixed types:
b or t-cell, Hodgkin AND NHL
relapsed, with no CNS involvement or active autoimmune disease
  Testing
PD-1 - Anti-Programmed Death-1 AND Ipilimumab 

Study drug reports  Background on mechanism: PAL  
129  Today: > 
bullet
Lymphoma, mixed types:
with no risk of autoimmune disease, no prior transplant, or CNS involvement
  Testing PD-L1 antibody (MPDL3280A)
Background: PAL   63  Today:  >  
bullet
Lymphoma, mixed types:
relapsed or refractory NHL or Hodgkin lymphoma
must have at least one measureable lesion > 1.5 cm 
  Testing PD-1 (Nivolumab) and Ipilimumab (two immune-checkpoint agents)
Study drug reports : 53  Today: > 
Return to Top
 
 




 
 
Includes transformed from indolent:
bullet
Lymphoma, mixed types:
CLL or Aggressive lymphoma including transformed, relapsed or refractory
  Testing Selinexor and Ibrutinib    (fixed link)

bullet
Lymphoma, mixed types:
DLBCL or transformed follicular with CD79 Mutation OR ABC subtype
  Testing
AEB071 ((a Protein Kinase C Inhibitor) + EVEROLIMUS  
: 16  Today: > 
bullet
Lymphoma, mixed
aggressive b-cell types, chemo refractory
  Testing engineered t-cells (CART19 /KTE-C19) in chemo-refractory Aggressive Lymphoma (NHL) – including transformed FL - ClinicalTrials.gov
Open  
81   Today: > 
Related Report
bullet
Lymphoma, mixed b-cell types:
ALL, CLL, NHL, relapsed refractory, follicular, nodal Marginal Zone

  Testing
Adoptive t-cell therapy: Laboratory Treated T Cells (anti-CD19-CAR autologous T cells)
Location: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium CNS lymphoma not specified but not excluded in the Eligibility section.

Study drug reports  740 Today: > 
Less common mixed types
bullet
Lymphoma, EBV-Associated
  Testing Adoptive t-cell therapy - LMP1/2-Specific

Study drug reports  53   Today: > 
bullet
Lymphoma, mixed types: T-cell or Hodgkins lymphoma:  relapsed or refractory
  Testing CPI-613 + Bendamustine

Study drug reports  : 19  Today: > 
bullet
Lymphoma, mixed types:
B or T-cell lymphoma, relapsed or refractory
Testing Romidepsin + Oral 5-Azacitidine (epigenetic agents) 
Study drug reports : 23  Today: > 
bullet
Lymphoma, mixed types:
Hodgkins OR NHL, second or subsequent relapsed after Stem cell Transplant
  Testing
Adoptive T-cell therapy: Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes
 
Study drug reports : 88 Today: > 
bullet
Lymphoma, mixed types, Hodgkin OR anaplastic large-cell  - relapsed - failed or declined transplant
  Testing
Brentuximab Vedotin (antibody-drug conjugate) WITH Bendamustine
 
Key eligibility:  relapsed HL or ALCL; for HL, failed or declined stem cell transplant
Study drug reports : 113  Today:  >
bullet
B-cell lymphoma:  MCL, Low Grade NHL, SLL/CLL), Transformed, DLBCL/PMBCL,
Hodgkin's Disease - relapsed and refractory
  Testing Everolimus WITH Rituxan maintenance AFTER High-dose Consolidative Therapy
Study drug reports  : 50  Today: > 
bullet
Lymphoma, mixed types:
B-cell, including MCL and transformed - poor risk, relapsed or refractory
  Testing
Zevalin WITH Rituxan-BEAM Chemotherapy, THEN Autologous Stem Cell Transplant

: 15  Today: >  (DONE)
bullet
Lymphoma, mixed types: FL, MCL, MZL, Relapsed/Refractory
  Testing
Lenalidomide + Rituximab folllowd by: Lenalidomide OR Rituxan Maintenance
Study drug reports   : 49  Today: > 

Return to Top

 

Lymphoma, mixed types
From our picks that are no longer recruiting
Lymphoma, mixed b-cell types, relapsed with CD19 expression
  Testing
Adoptive CART t-cell - Cellular Immunotherapy Following Cyclophosphamide
Clicks as of 6/11/14: 37  Today: > (DONE)
Lymphoma, mixed indolent b-cell types: previously untreated indolent with low tumor burden
Comparing GA101 (type II cd20 antibody) to Rituxan
Clicks as of 4/27/14: 105  Today: >  (DONE)
b-cell lymphoma cd20 positive, relapsed or refractory
Testing: Ublituximab (re-engineered cd20 antibody)  
Study drug reports Clicks as of 4/27/14: 91 Today:  > 
b-cell lymphoma - DLBCL, indolent NHL, MCL, relapsed
Testing: Ibrutinib WITH Rituxan-Bendamustine
 Clicks as of 4/27/14: 109 Today: > 
b-cell lymphoma, relapsed and refractory
Testing: GS-9973 (oral syk inhibitor) WITH Idelalisib (b-cell receptor kinase inhibitor)
  Clicks as of 4/27/14: 86  Today: > 
b-cell lymphoma, low or high grade - including DLBCL, relapsed and refractory
Testing: DCDT2980S OR DCDS4501A (antibody - drug conjugates) WITH Rituxan
Clicks as of 4/27/14: 59  Today: > 
b-cell aggressive lymphoma,
relapsed and refractory, high-risk, intermediate grade (including transformed follicular)

Testing: Adoptive T-cell therapy: Genetically Engineered Lymphocyte Therapy AFTER Transplant
Clicks as of 4/27/1436 Today: >  
b-cell NHL OR CLL cd-19 positive, high-risk, refractory to chemotherapy WITH at least 2 prior therapies
Testing: Adoptive T-cell therapy:  Genetically Engineered Lymphocyte Therapy (CART)
Clicks as of 4/27/14
256  Today: >  
b-cell NHL, indolent - FL, CLL, LPL, MZL - at least 2 prior therapies, not transformed
Testing: Idelalisib (GS01101 / CAL-101)

Clicks as of 1/20/13 26  Today:  > 
b-cell NHL - DLBCL, indolent or aggressive cd20 positive lymphoma, no prior combination chemo
Testing:
Ibrutinib WITH R-CHOP
Clicks as of 10/18/13: 48 Today: 
b-cell, NHL / CLL, relapsed or refractory
Testing: DCDS4501A (cd79b antibody - drug conjugate) escalating doses

Study drug reports Clicks as of 10/18/13: 100  Today: >
Lymphoma, mixed types:
DLBCL or transformed follicular with CD79 Mutation
Testing AEB071 - a Protein Kinase C Inhibitor
Clicks as of 4/27/1467   Today: >  (Terminated)
Lymphoma, mixed B-cell types: MCL,
indolent NHL or DLBCL - relapsed and refractory
  Testing ABT-199 WITH Bendamustine-Rituximab
  Clicks as of 4/27/14: 159  Today: >  (DONE)
Lymphoma, mixed types:
B-cell Non-Hodgkins Lymphoma or CLL

  Testing Urelumab and Rituximab
Key eligibility: relapsed/refractory B-cell Malignancies; Follicular Lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)  patients must have at least 1 lesion that can be biopsied at screening and on treatment urelumab

Study drug reports : 22 Today: >  (DONE)

 


 
 Mantle Cell Lymphoma (MCL)

 See also lymphoma - mixed types, aggressive, and indolent

bullet
Locate trials for MCL
Open Phase III Controlled trials
By treatment status: Untreated | Relapsed
bullet
MCL, relapsed or refractory
Testing KTE-C19 (CAR t19) in Relapsed/Refractory Mantle Cell Lymphoma Open 
: 18 Today: > 
 
bullet
MCL, relapsed or refractory
Testing Ibrutinib (BTK Inhibitor) With Carfilzomib (Velcade-like) in Relapse/Refractory Mantle Cell Lymphoma Open 
: 32 Today: > 

report http://1.usa.gov/1uAmwf0 
bullet
MCL previously untreated, over 60 years of age
Testing
Bortezomib (Velcade) WITH Bendamustine-Rituxan Followed by Rituximab and Lenalidomide

Study drug reports Clicks as of 10/19/13: 28  Today: > 

Return to Top
 

 

 

 

MCL
From our picks that are no longer recruiting
 
MCL, Newly Diagnosed
Testing
Ibrutinib With Bendamustine and Rituxan
Locations:
 Many sites in US and aboard but you must email sponsor for centers 
Clicks as of 10/22/13: 45  Today: >  (DONE)
MCL relapsed
Testing
Lenalidomide and Rituximab WITH or WITHOUT Idelalisib (CAL101)
Locations:  Alliance trial - more sites should open soon
Clicks as of 5/9/2013: 28  Today:  >  (DONE)
MCL previously untreated,  OR did not achieve partial response after most recent treatment
Testing: Ibrutinib (btk-inhibitor / PCI-32765)

Study drug reports  Clicks as of 1/20/13: 30 Today: > 
 
MCL relapsed, progressed after last Velcade Therapy
Testing: Ibrutinib (btk-inhibitor) Who Progress After Bortezomib (Velcade)

Study drug reports Clicks as of 10/19/13:  25  Today:  > 
 



 Marginal Zone Cell Lymphoma (MZL) / MALT
 
  See also:  
studies for mixed, aggressive, and indolent

bullet
Locate trials for MZL / MALT 
Open Phase III controlled trials
By treatment status:
Untreated  | Relapsed
bullet
Marginal Zone, untreated, Ocular Adnexal
Testing First-line Doxycycline (antibiotic)  Open
Clicks as of 2/4/2106  NEW  Today >
bullet
Marginal zone and other indolent lymphoma
Testing Lenalidomide and Rituximab  Open
Clicks as of 2/4/2106  NEW  Today >
bullet
Marginal Zone and other indolent lymphoma,
Testing Rituximab and Zevalin Open
Clicks as of 2/4/2106  NEW  Today >
bullet
Marginal Zone and other indolent lymphoma,
Testing Rituximab Plus Lenalidomide versus Rituxan + placebo (RCT)  Open
Clicks as of 6/2/2016: New  Today >

 

Return to Top

 

 
 
MZL (MALT)
From our picks that are no longer recruiting
 

Marginal Zone lymphoma, relapsed and refractory    
Testing Ibrutinib
Clicks as of 6/2/201614  Today:  > 

Marginal Zone Lymphoma, refractory to last systemic therapy
Testing
Ibrutinib
Clicks as of 6/2/2016356  Today:    (DONE)
MALT, previously treated or untreated
Testing
Rituxan + Lenalidomide
Study drug reports   Clicks as of 6/2/2016 20  Today:  (DONE)

 

 


T-Cell Lymphoma

See also Lymphoma - mixed, aggressive, and indolent

bullet
Locate trials for T-cell lymphoma
Open Phase III Controlled trials
By treatment status:
bullet
T-cell lymphoma, mixed types, relapsed or refractory, PTCL only for expansion phase
Testing
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies - PTCL only for expansion phase Open
Clicks as of 6/2/2016: 29  Today >

Columbia University Medical Center Recruiting
New York, New York, United States, 10019
Contact: Ameet Narwal 212-326-5720 an2284@columbia.edu
Principal Investigator: Jennifer E Amengual, MD
bullet
T-cell lymphoma, untreated, cd30 positive mature type
Comparing
Brentuximab + CHP VS CHOP 
Study drug reports  Clicks as of 6/2/201615  Today: > 
bullet
T-cell lymphoma, peripheral type, previously untreated
Comparing
Romidepsin + CHOP VS CHOP 

Study drug reports   Clicks as of 6/2/201616  Today: > 

Return to Top
 

 
 
T-cell Lymphoma
From our picks that are no longer recruiting
T-cell lymphoma, Mycosis Fungoides or Sézary Syndrome, Relapsed or Refractory, Stage IIB-IVB
Testing Lambrolizumab
(PD1 antibody)  Open
Clicks as of 6/2/2016: 39  Today >  (Done)
T-cell lymphoma cutaneous (CTCL)  Early-Stage (IA-IIA), relapse after 1 or more treatments
Testing
O6-Benzylguanine AND Topical Carmustine

Study drug reports  Clicks as of 4/29/14: 20 Today:  >  
T-cell lymphoma Peripheral type, relapsed or refractory
Testing:
Alisertib (Aurora Kinase A Inhibitor - MLN8237

Study drug reports  Clicks as of 4/29/1428  Today:  > 
T-cell lymphoma PTCL and other aggressive types, previously untreated
Testing: SAHA (Vorinostat) WITH CHOP

Study drug reports  Clicks as of 10/19/13: 30 Today: 

T-cell lymphoma, peripheral type, previously untreated
Comparing
Pralatrexate to Observation Following CHOP-based treatment 
Clicks as of 6/2/201611  Today: >  (Terminated)


 
 


Waldenstrom's

bullet
Locate WM trials
By treatment status:
bullet
Waldenström’s Macroglobulinemia -
 ClinicalTrials.gov All open studies
bullet
Locate Open Controlled (phase III) Studies

 

 

 


Other Indications, GVHD

GVHD (Graft versus Host Disease)
bullet
GVHD Phase 3 studies (controlled)
Locate Open Studies
bullet
Acute GVHD 
Locate Open Studies
bullet
Chronic GVHD 
Locate Open Studies
bullet
Steroid refractory GVHD 
Locate Open Studies
Studies of interest:
bullet
Graft versus Host Disease acute, steroid-refractory
Testing Brentuximab Vedotin for Steroid Refractory GvHD

Study drug reports   Clicks as of 10/19/1314 Today:  > 

Return to Top
 

 

Related Resources 

bullet
How long does it take to complete a typical study?    
How many completed studies advance practice or inform future studies? 

Study Results for Lymphoma and CLL trials 
bullet
7 reasons to participate in clinical trials
bullet
Clinical Trials - News Medical: Helping cancer patients tackle geographic challenges to access clinical trials
bullet
News Medical:  Phase III study using ibrutinib in CLL patients completed  http://bit.ly/ZK8qZy
bullet
Dr. Sharman's CLL & Lymphoma Blog: New Study Available for CLL/NHL http://bit.ly/17BoHUi

Return to Top

 
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.